Jay Bradner, head of Novartis’ drug discovery, talks to pharmaphorum about the firm’s drive to transform itself into 'a medicine and data science company'.
A new whitepaper presenting analysis of exclusive M3 (EU) data, revealing the digital and technological habits and preferences of doctors and how pharma can best engage.
